All In Biotech

Drug Trial Radar · NCT04386070

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 281 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

281

Actual

Start

May 16, 2022

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Christian Medical College and Hospital, Ludhiana, India; Ministry of Health, Ghana; University of Lagos, Nigeria; Kigali University Teaching Hospital; Hospital Español Veracruz; Université d'Abomey-Calavi; University of Witwatersrand, South Africa; University of Edinburgh; Istituto Clinico Humanitas; University of Cape Town
First posted
May 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to reduce pulmonary complications in adult patients undergoing abdominal or thoracic surgery in COVID-19 exposed hospital environments. A Trial in Low and Middle Income Countries (LMICs)

Conditions

  • Pulmonary Complications in Surgical Patients
  • COVID
  • Severe Acute Respiratory Syndrome

Interventions

  • RESP301Drug

    RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or deathTime frame: From randomisation until discharge from hospital, average less than 30 days

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • University Of Abuja Teaching Hospital (Spoke)

    Gwagwalada, Nigeria

  • Lagos University Teaching Hospital (Hub)

    Lagos, Nigeria

  • Nnamdi Azikiwe University Teaching Hospital (Spoke)

    Nnewi, Nigeria

  • University Teaching Hospital of Butare (CHUB) (Spoke)

    Butare, Rwanda

  • Kibungo Referral Hospital (Spoke)

    Kibungo, Rwanda

  • Kibagabaga Hospital (Spoke)

    Kigali, Rwanda

  • University Teaching Hospital of Kigali (Hub)

    Kigali, Rwanda

  • Kibogora District Hospital (Spoke)

    Kirambo, Rwanda

  • Ruhengeri Referral Hospital (Spoke)

    Ruhengeri, Rwanda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.